Readers of the New England Journal of Medicine should be forewarned: The information in the pages of the NEJM is tainted by industry influence, its professional and scientific integrity are tainted.
A follow-up to news reports about the conflict of interest scandal that has engulfed not only Dr. Charles Nemeroff, former president and editor in chief of the official journal of the American College of Neuropsychopharmacology, but the College itself.
A notice from The American College of Neuropsychopharmacology, the inner sanctum of biological–predominantly drug-centered psychiatry–informs the
membership of the resignation of Dr. Charles Nemeroff, the Editor-in-Chief of its journal, Neuropsychopharmacology.
A Boston Globe report (below) focuses on three recent reports in the Journal of the American Medical Association (JAMA) by Harvard researchers who violated the journal’s disclosure policy by failing to disclose their financial ties to companies that had the most to gain from their purported findings.
The harm done by journals’ failure to protect the integrity of science can hardly be overstated.
Today’s New York Times editorial hits the mark–it’s right on target!
The Associated Press reports (1, 2 below) that the FDA has just issued new warnings about two additional life-threatening risks induced by SSRI antidepressants: Serotonin Syndrome and Persistent Pulmonary Hypertension in newborn babies.
The Wall Street Journal and Bloomberg News report about a case involving Neuropsychopharmacology, the official journal of the American College of Neuropsychopharmacology (ACNP) that will likely go down in history as psychiatry’s Watergate.
Operating like thieves under the cover of darkness, prominent academic-based "authorities" in medical specialties have debased academic standards and sold their reputations for cash-
Following on the heels of an investigative report by David Armstrong of The Wall Street Journal <https://ahrp.org/cms/content/view/286/27/> the Associated Press reports that JAMA claims it was misled.
"Drug companies should not be allowed to evaluate their own products."
Compare and contrast two recent news reports about TeenScreen: Lidia Wasowicz of United Press International provides readers with a sense of the controversy generated by psychiatry’s latest market expansion scheme.
